Detalles de la búsqueda
1.
Framework of the Strengths and Challenges of Clinically Integrated Trials: An Expert Panel Report.
Am Heart J
; 2024 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38795793
2.
Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank.
Clin Infect Dis
; 77(12): 1635-1643, 2023 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37435958
3.
Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomesâ°.
Mult Scler Relat Disord
; 45: 102346, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32717684
4.
Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study.
Mult Scler Relat Disord
; 25: 50-56, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-30036854
5.
Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial.
Ther Adv Neurol Disord
; 11: 1756286418774338, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29844796
6.
Efficacy of combination therapy with amlodipine besylate/benazepril hydrochloride for lowering systolic blood pressure in stage 2 hypertension.
Am J Geriatr Cardiol
; 15(3): 142-50, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-16687966
7.
Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study.
J Clin Hypertens (Greenwich)
; 7(11): 641-6; quiz 647-8, 2005 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-16278521
8.
Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
Am J Hypertens
; 17(6): 495-501, 2004 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-15177521
9.
First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
Mult Scler Relat Disord
; 3(5): 620-8, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26265274
10.
Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design.
J Med Econ
; 16(7): 859-65, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23647445
Resultados
1 -
10
de 10
1
Próxima >
>>